CK Life Sciences Int'l., (Holdings) Inc. (HKG:0775)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 7.98B +82.4% |
| Revenue (ttm) | 5.49B +2.1% |
| Net Income | -278.39M |
| EPS | -0.03 |
| Shares Out | 9.61B |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 4,308,000 |
| Average Volume | 3,802,355 |
| Open | 0.8300 |
| Previous Close | 0.8300 |
| Day's Range | 0.8300 - 0.8400 |
| 52-Week Range | 0.4500 - 1.1000 |
| Beta | 0.21 |
| RSI | 46.37 |
| Earnings Date | Mar 18, 2026 |
About HKG:0775
CK Life Sciences Int'l., (Holdings) Inc., an investment holding company, researches, develops, manufactures, commercializes, and sells health and agriculture-related products in the Asia Pacific and North America. It manufactures and markets plant protection products and soluble fertilizers; manufactures, blends, distributes, and sells fertilizers, pesticides, and related agricultural products; manufactures and distributes horticultural products for the home gardening market; and produces non-sterile prescription and over-the-counter medicines.... [Read more]
Financial Performance
Financial StatementsNews
CK Life unit merges with TransCode as Li Ka-shing firm eyes anticancer drugs
CK Life Sciences International is set to merge its subsidiary Polynoma with Nasdaq-listed TransCode Therapeutics, in a move expected to boost the pipeline of anticancer drugs, according to the biotech...
TransCode Acquires Polynoma From CK Life Sciences
(RTTNews) - TransCode Therapeutics (RNAZ) has entered into a definitive agreement to acquire Polynoma, a privately-held biotechnology immuno-oncology company. Polynoma is developing a late-stage candi...
CK Life’s new CEO counts on Big Pharma experience to boost new drug success, earnings
Lance Yuen spent two decades at Bristol-Myers Squibb and Bayer in the region before becoming the CEO at CK Life Sciences last month.